Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease

• US 20050042284A1
• Filed: 07/12/2004
• Published: 02/24/2005
• Est. Priority Date: 07/11/2003
• Status: Abandoned Application

• Current Assignee: Myriad Genetics
• Original Assignee: Myriad Genetics
• Inventors: Zavitz, Kenton, Hobden, Adrian, Hendrix, Suzanne, Mather, Gary
• Application Number:
  US10/889,971
• Publication Number:
  US 20050042284A1
• Time in Patent Office: Days
• US Class Current: 424/464
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 9/2009 Inorganic compounds
• CPC Class Codes: A61K 9/2013 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/2813 Inorganic compounds
• CPC Class Codes: A61K 9/282 Organic compounds, e.g. fats
• CPC Class Codes: A61K 9/2866 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

In general, the invention relates to a pharmaceutical dose having R-flurbiprofen as the active ingredient that upon oral administration of a single dose to a fasting subject provides a C_max of about 30-95 μg per mL. When the dose is administered to an individual having mild-to-moderate Alzheimer'"'"'s disease (or desiring protection against Alzheimer'"'"'s disease) twice daily for at least 4 months according to the described guidelines, an improvement or lessening in decline of cognitive function as characterized by cognition tests is observed in the patient. The composition of the invention is formulated with one or more pharmaceutically acceptable excipients, salts or carriers.

Claims

1. A pharmaceutical unit dosage form comprising R-flurbiprofen as the active ingredient, and one or more pharmaceutically acceptable excipients, wherein said pharmaceutical unit dosage form, when orally administered to a fasting subject, provides a plasma C_max of about 30 to about 95 μ

g per mL.

2. The pharmaceutical unit dosage form of claim 1 comprising from about 400 to about 800 mg R-flurbiprofen.

3. The pharmaceutical unit dosage form of claim 1 comprising about 350 mg R-flurbiprofen.

4. The pharmaceutical unit dosage form of claim 1 comprising about 400 mg R-flurbiprofen.

5. The pharmaceutical unit dosage form of claim 1 comprising about 450 mg R-flurbiprofen.

6. The pharmaceutical unit dosage form of claim 1 comprising about 500 mg R-flurbiprofen.

7. The pharmaceutical unit dosage form of claim 1 comprising about 550 mg R-flurbiprofen.

8. The pharmaceutical unit dosage form of claim 1 comprising about 600 mg R-flurbiprofen.

9. The pharmaceutical unit dosage form of claim 1 comprising about 650 mg R-flurbiprofen.

10. The pharmaceutical unit dosage form of claim 1 comprising about 700 mg R-flurbiprofen.

11. The pharmaceutical unit dosage form of claim 1 comprising about 800 mg R-flurbiprofen.

12. The pharmaceutical unit dosage form of claim 1 comprising about 850 mg R-flurbiprofen.

13. The pharmaceutical unit dosage form of any one of claims 1-12 wherein said unit dosage form comprises R-flurbiprofen substantially free of the (S) stereoisomer.

14. The pharmaceutical unit dosage form of claim 1 wherein (S)-flurbiprofen is no more than 10.0% by weight of total flurbiprofen in said pharmaceutical unit dosage form.

15. The pharmaceutical unit dosage form of claim 1 wherein (S)-flurbiprofen is no more than 1.0% by weight of total flurbiprofen in said pharmaceutical unit dosage form.

16. A method of treating an individual with a neurodegenerative disorder, comprising administering to said individual the pharmaceutical unit dosage form of any of claim 1, 2 or 13, wherein said pharmaceutical unit dosage form is administered for a time and in an amount sufficient to cause an improvement, or a lessening in the decline, in a test of cognition.

17. The method of claim 16, wherein said neurodegenerative disorder is Alzheimer'"'"'s disease.

18. The method of claim 16 wherein said pharmaceutical unit dosage form is administered for at least 30 days.

19. The method of claim 16 wherein said pharmaceutical unit dosage form is administered for at least 60 days.

20. The method of claim 16 wherein said pharmaceutical unit dosage form is administered for at least 90 days.

21. The method of claim 16 wherein said pharmaceutical unit dosage form is administered for at least 120 days.

22. The method of claim 16 wherein said pharmaceutical unit dosage form is administered for at least 150 days.

23. The method of claim 16 wherein said pharmaceutical unit dosage form is administered for at least 180 days.

24. The method of claim 16 wherein said pharmaceutical unit dosage form is administered for at least 210 days.

25. The method of claim 16 wherein said pharmaceutical unit dosage form is administered for at least 240 days.

26. The method of claim 16 wherein said pharmaceutical unit dosage form is administered for at least 300 days.

27. The method of claim 16 wherein said pharmaceutical unit dosage form is administered for at least 400 days.

28. The method of claim 16 wherein said pharmaceutical unit dosage form is administered for at least 500 days.

29. The method of claim 16 wherein said pharmaceutical unit dosage form is administered for at least 600 days.

30. The method of claim 16 wherein said test of cognition is an ADAS-cog test.

31. The method of claim 16 wherein said test of cognition is a CDR sum of boxes test.

32. The method of claim 16 wherein said lessening in decline of cognitive function is at least about 20-60% as measured by the ADAS-cog test.

33. The method of claim 16, wherein said individual is a person diagnosed as having mild or moderate Alzheimer'"'"'s disease.

34. The method of claim 16, wherein said individual has a score of from 26 to 10, inclusive, on the Mini Mental State Exam (MMSE).

35. The method of claim 16, wherein said individual has a score of from 26 to 19, inclusive, on the MMSE.

36. The method of claim 16, wherein said individual has a score of from 18 to 10, inclusive, on the MMSE.

37. The method of claim 16, wherein said individual is currently taking a drug for said neurodegenerative disorder, wherein said drug does not contain flurbiprofen.

38. The method of claim 16, wherein said individual is from 55 to 80 years of age.

39. The method of claim 16, wherein said individual is concurrently taking a second drug for the treatment of Alzheimer'"'"'s disease.

40. The method of claim 16, wherein sad individual has, prior to taking R-flurbiprofen, taken a second drug for the treatment of Alzheimer'"'"'s disease.

41. The method of claim 39 or claim 40, where said second drug is an acetylcholinesterase inhibitor.

42. The method of claim 41, wherein said acetylcholinesterase inhibitor is Galanthamine, galantamine, Reminyl, E2020, Donepezil, Aricept, Physostigmine, Tacrine, tetrahydroaminoacridine, THA, Rivastigmine, Phenserine, Metrifonate, Promem, Huperazine, or a combination of one or more of the foregoing.

43. The method of claim 16, wherein said individual is concurrently taking a non-drug substance for the treatment of Alzheimer'"'"'s disease.

45. The method of claim 43 or 44, where said non-drug substance in an antioxidant.

46. The method of claim 45, wherein said anti-oxidant is vitamin C.

47. The method of claim 46, wherein said vitamin C is taken at a dose of 500-1000 mg per dose of R-flurbiprofen.

48. The method of claim 45, wherein said anti-oxidant is vitamin E.

49. The method of claim 46, wherein said vitamin E is taken at a dose of 400-800 IU per dose of R-flurbiprofen.

50. The method of claim 16, wherein said individual does not have a condition selected from the group consisting of epilepsy;

focal brain lesion;

DSM-IV (TR) criteria for any major psychiatric disorder;

a history of hypersensitivity to flurbiprofen or other NSAIDs;

a history of upper GI bleeding requiring transfusion or surgery;

active gastric or duodenal ulcer disease;

a history of NSAID-associated ulcers;

active malignancy;

a history of active malignancy, except for basal cell carcinoma or squamous cell carcinoma of the skin;

chronic or acute renal, hepatic or metabolic disorder;

an uncontrolled cardiac condition;

current anticoagulant therapy; and

current treatment with any CYP2C9 inhibitor.

51. The pharmaceutical unit dosage form of claim 1 in tablet form.

52. The pharmaceutical unit dosage form of claim 1 wherein said C_max is achieved between 1.75 and 3.75 hours after administration.

53. The pharmaceutical unit dosage form of claim 1 wherein said C_max is achieved between 1.0 and 3.0 hours after administration.

63. The pharmaceutical unit dosage form of claim 1 or claim 54, wherein said C_max is achieved by about 1 hour to about 3.75 hours after administration.

64. The pharmaceutical unit dosage form of claim 63, wherein said C_max is achieved by about 1.75 to about 3.75 hours after administration.

65. The pharmaceutical unit dosage form of claim 63, wherein said C_max is achieved by about 1.0 to about 3.0 hours after administration.

90. The method of claim 16, wherein said pharmaceutical unit dosage form is 400 mg and is administered twice per day.

91. The method of claim 16, wherein said pharmaceutical unit dosage form is 400 mg and is administered twice per day.

44. The method of 16 where said individual has, prior to taking R-flurbiprofen, taken a non-drug substance for the treatment of Alzheimer'"'"'s disease.

54. A pharmaceutical unit dosage form comprising R-flurbiprofen as the active ingredient, and one or more pharmaceutically acceptable excipients, wherein said pharmaceutical dose, when orally administered to a fasting subject, provides a plasma C_max of about 100 to about 600 μ

M.

55. The pharmaceutical unit dosage form of claim 54, wherein said C_max is from about 160 to about 320 μ

M.

56. The pharmaceutical unit dosage form of claim 54, wherein said C_max is from about 200 to about 240 μ

M.

57. A pharmaceutical unit dosage form comprising R-flurbiprofen as the active ingredient, and one or more pharmaceutically acceptable excipients, wherein said pharmaceutical unit dosage form, when orally administered to a fasting subject, provides a C_max in cerebrospinal fluid of about 0.05 to about 7.5 μ

g per mL.

58. The pharmaceutical unit dosage form of claim 57, wherein said C_max in cerebrospinal fluid is from about 0.08 to 4.5 μ

g per mL.

59. The pharmaceutical unit dosage form of claim 57, wherein said C_max in cerebrospinal fluid is from about 0.20 to 3.0 μ

g per mL.

66. The pharmaceutical unit dosage form of claim 57 or claim 60, wherein said C_max is achieved by about 1 hour to about 6 hours after administration.

60. A pharmaceutical unit dosage form comprising R-flurbiprofen as the active ingredient, and one or more pharmaceutically acceptable excipients, wherein said pharmaceutical unit dosage form, when orally administered to a fasting subject, provides a C_max in cerebrospinal fluid of about 2 to about 30 μ

M.

61. The pharmaceutical unit dosage form of claim 60, wherein said C_max in cerebrospinal fluid is from about 3.2 to about 20 μ

M.

62. The pharmaceutical unit dosage form of claim 60, wherein said C_max in cerebrospinal fluid is from about 4 to about 12 μ

M.

67. A method of administering R-flurbiprofen to an individual in need thereof comprising orally administering R-flurbiprofen to said individual in an amount sufficient to achieve a plasma C_max of about 25 to about 150 μ

g per mL in 1.0 to 3.75 hours after administration.

68. The method of claim 67, wherein said C_max is about 40 to about 95 μ

g per mL.

69. The method of claim 67, wherein said C_max is about 50 to about 80 μ

g per mL.

70. The method of claim 67, wherein said plasma C_max is achieved 1.0 to 3.75 hours after administration.

71. The method of claim 67, wherein said plasma C_max is achieved 1.75 to 3.75 hours after administration.

72. The method of claim 67, wherein said plasma C_max is achieved 1.0 to 3.0 hours after administration.

84. The method of any of claims 67, 73, 79 or 81, wherein said individual exhibits mild to moderate dementia.

85. The method of claim 84, wherein said dementia is Alzheimer'"'"'s disease.

92. The method of any of claims 67, 73, 79 or 81, wherein said amount is 400 mg.

93. The method of any of claims 67, 73, 79 or 81, wherein said amount is 800 mg.

73. A method of administering R-flurbiprofen to an individual in need thereof comprising orally administering R-flurbiprofen to said individual in an amount sufficient to achieve a plasma C_max of about 100 to about 600 μ

M in 1.0 to 3.75 hours after administration.

74. The method of claim 73, wherein said C_max is about 160 to about 380 μ

M.

75. The method of claim 73, wherein said C_max is about 200 to about 240 μ

M.

76. The method of claim 73, wherein said plasma C_max is achieved 1.0 to 3.75 hours after administration.

77. The method of claim 73, wherein said plasma C_max is achieved 1.75 to 3.75 hours after administration.

78. The method of claim 73, wherein said plasma C_max is achieved 1.0 to 3.0 hours after administration.

79. A method of administering R-flurbiprofen to an individual in need thereof comprising orally administering R-flurbiprofen to said individual in an amount sufficient to achieve a C_max in cerebrospinal fluid of about 0.05 to about 7.5 μ

g per mL in about 1.0 to about 6 hours after administration.

80. The method of claim 79, wherein said C_max in cerebrospinal fluid is about 0.08 to about 4.5 μ

g per mL.

81. A method of administering R-flurbiprofen to an individual in need thereof comprising orally administering R-flurbiprofen to said individual in an amount sufficient to achieve a C_max in cerebrospinal fluid of about 2 to about 30 μ

M in about 1.0 to about 6 hours after administration.

82. The method of claim 81, wherein said C_max in cerebrospinal fluid is about 3.2 to about 20 μ

M.

83. The method of claim 81, wherein said C_max in cerebrospinal fluid is about 4.0 to about 12 μ

M.

88. The pharmaceutical unit dosage form of claim 83 or claim 84 additionally comprising a coating.

89. The pharmaceutical unit dosage form of claim 83 or claim 84 that is encapsulated in gelatin.

86. A pharmaceutical unit dosage form of R-flurbiprofen composed of about 400 mg R-flurbiprofen;

microcrystalline cellulose;

colloidal silicon dioxide; and

magnesium stearate.

87. A pharmaceutical unit dosage form of R-flurbiprofen composed of about 200 mg R-flurbiprofen;

microcrystalline cellulose;

colloidal silicon dioxide; and

magnesium stearate.